Alexion Pharmaceuticals (ALXN) Price Target Raised to $155.00 at Stifel Nicolaus

Lloyd Doyle
May 18, 2018

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. Sold All: 65 Reduced: 171 Increased: 178 New Position: 64. The biopharmaceutical company reported $1.68 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.50 by $0.18. Funds hold 204.38 million shares thus 1.21% less from 2017Q3's 206.89 million shares. The Massachusetts-based Liberty Mutual Group Inc Asset has invested 0.03% in Alexion Pharmaceuticals, Inc.

Want to see what other hedge funds are holding ALXN? During the same quarter in the previous year, the business posted $1.38 earnings per share. analysts predict that Alexion Pharmaceuticals will post 6.28 earnings per share for the current fiscal year. (NASDAQ:ALXN). Louisiana State Employees Retirement System stated it has 0.07% of its capital in Alexion Pharmaceuticals, Inc. Stephens Invest Mngmt Gp Ltd Liability Corp owns 17,712 shares or 0.05% of their United States portfolio. Wms Prns Ltd Liability reported 2,275 shares. $27.33 billion is the MC of Alexion Pharmaceuticals Inc (Put). Janney Montgomery Scott Ltd Liability Corp has 0.02% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 3,749 shares. (NASDAQ:ALXN) for 57,516 shares. 3 = Hold. Analysts' recommendations are the fountainhead of equity research reports and should be used in tangent with proprietary research and investment methodologies in order to make investment decisions. Gateway Investment Advisers Limited Com holds 143,199 shares.

Since January 2, 2018, it had 1 insider buy, and 12 sales for $3.41 million activity.

In related news, Director Christopher J. Coughlin bought 10,000 shares of the company's stock in a transaction dated Monday, April 30th.

The company had seen its current volume reaching at 1.64 million shares in the last trade. 1,651 shares were sold by Goff Brian, worth $192,028. O'Neill Julie also sold $248,474 worth of Alexion Pharmaceuticals, Inc. On Monday, ALXN stock construct a change of 2.67 in a total of its share price and finished its trading at 122.85. (NASDAQ:ALXN) news were published by: which released: "Vertex Pharma (VRTX), Alexion Pharma (ALXN) Least Impacted from Trump Drug Policies - RBC" on May 15, 2018, also published article titled: "How Alexion Pharmaceuticals Knocked It Out of the Park in Q1", published: "Benzinga's Insider Buys Of The Week: Alexion Pharmaceuticals, And More" on May 06, 2018.

The stock of Alexion Pharmaceuticals Inc (NASDAQ:ALXN) registered an increase of 1.61% in short interest. Its up 1.61% from 4.57M shares, reported previously. About 1.45 million shares traded. That compares with the recent volume average of 2.21 million. As it's [published] in Securities and Exchange filling the stake in Arena Pharmaceuticals Inc () is upped by 22,017 shares to 50,000 shares. (NASDAQ:ALXN) was released by: and their article: "3 Top Healthcare Stocks to Buy Right Now" with publication date: May 01, 2018. About 423,130 shares traded. Carver Bancorp, Inc. (CARV) has declined 8.59% since May 16, 2017 and is downtrending. It has underperformed by 20.39% the S&P500. Finally, CIBC World Markets Inc. purchased a new position in Alexion Pharmaceuticals during the 4th quarter valued at about $263,000.

Technical Analysis: The Company has the market capitalization of $27.28B. The firm offers Soliris, a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease.The P/E ratio is 62.36. It has a 61.89 P/E ratio. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency.

ALXN has been the topic of a number of analyst reports. Therefore 86% are positive.

RSP Permian, Inc. (RSPP) stock demonstrated 66.13% move opposition to 12-month low and unveiled a move of -7.24% versus to 12-month high.

Analyst's mean target price for the company is $159.15 while analysts mean suggestion is 1.8. (NASDAQ:ALXN) earned "Buy" rating by Piper Jaffray. Finally, Raymond James Trust N.A. grew its holdings in shares of Alexion Pharmaceuticals by 26.3% in the fourth quarter. The firm has "Underperform" rating by FBR Capital given on Thursday, September 15. On Thursday, February 8 the rating was maintained by Jefferies with "Hold". The stock of Alexion Pharmaceuticals, Inc. CNB Bank purchased a new position in Alexion Pharmaceuticals during the 4th quarter valued at about $150,000. (NASDAQ:ALXN). Bailard owns 2,200 shs. The firm has "Outperform" rating by Robert W. Baird given on Monday, December 18. As per Thursday, January 18, the company rating was reinitiated by Credit Suisse. Evercore maintained it with "Buy" rating and $15000 target in Tuesday, May 8 report. TIAA CREF Investment Management LLC now owns 3,836,919 shares of the biopharmaceutical company's stock worth $458,857,000 after purchasing an additional 414,969 shares during the last quarter. (NASDAQ:ALXN) shs. On Tuesday, February 6 Franchini Indrani Lall sold $169,696 worth of Alexion Pharmaceuticals, Inc.

Gabriel Smith joined the, after more than 10 years of experience in writing financial and business news, most recently as Investment Editor and writer.

Other reports by Iphone Fresh

Discuss This Article